Gri­fols snags the rest of Gi­ga­Gen in $80M ac­qui­si­tion; Ver­tex moves cut­ting-edge di­a­betes treat­ment in­to the clin­ic

Spain’s Gri­fols is putting up $80 mil­lion to buy out the 56% of eq­ui­ty in Gi­ga­Gen it doesn’t al­ready own.

Gri­fols ex­ecs tout­ed its ac­qui­si­tion of a pipeline that in­cludes “the world’s first re­com­bi­nant im­munoglob­u­lin and a port­fo­lio of im­muno-on­co­log­i­cal ther­a­pies.”

The Span­ish biotech an­ted up $35 mil­lion back in the sum­mer of 2017 to buy in­to Gi­ga­Gen, tak­ing its first 44% mi­nor­i­ty stake. And ex­ecs say they won’t have to take on new debt in the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.